FULC vs PTCT
FULC: Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking gene expression to treat serious, rare genetic diseases. PTCT: A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases.
Side-by-side fundamentals
| Metric | FULC | PTCT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $3.58 | $68.01 | |
| Market cap as of 2026-08-03 | $273M | $5.7B | |
| PEG as of 2026-08-03 | n/a | 0.86 | |
| Net margin as of 2026-08-03 | +8.1% | -14.5% | FULC higher |
| Gross margin as of 2026-08-03 | n/a | +73.2% | |
| Operating margin as of 2026-08-03 | -3.6% | -1.6% | PTCT higher |
| ROE as of 2026-08-03 | -22.5% | -351.9% | FULC higher |
| ROA as of 2026-08-03 | -21.2% | -4.3% | PTCT higher |
| Debt / equity as of 2026-08-03 | 0.00 | 848.93 | FULC lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | -53.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.3% | |
| Beta as of 2026-08-03 | 1.34 | 0.98 | |
| 1-year return as of 2026-07-31 close | -46.8% | +30.5% | PTCT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.